Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc’s blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.
The pair’s Indian rival Dr. Reddy’s Laboratories is currently locked in a legal battle in the United States to re-launch a cheaper version of the UK drugmaker’s Suboxone Film.
Indivior also reiterated its full-year net revenues guidance of $25 million to $50 million from its new opioid addiction drug Sublocade, on which the company has pinned its hopes after the legal battles.
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe todaySubscribe now